1. Home
  2. Program

Tags : Program

Jounce Stops Enrollment in P-II EMERGE Study Evaluating Vopratelimab for Lung Cancer
Clinical Trials

Jounce Stops Enrollment in P-II EMERGE Study Evaluating Vopratelimab for

Tuba Khan November 4, 2020

Shots: The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the study showed that the trial will not meet pre-specified interim criteria for continuation of enrollment The company also reported the first patient dosing in P-II SELECT study assessing Vopratelimab + […]Read More

Eli Lilly Collaborates with Dexcom for Diabetes Management
MedTech

Eli Lilly Collaborates with Dexcom for Diabetes Management

Tuba Khan October 8, 2020

Shots: The companies will partner to promote Lyumjev (insulin lispro-aabc injection, 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes, including giving visibility to the benefits of a new mealtime insulin HCPs treating T1D & T2D will be able to assess their patient’s glucose levels […]Read More

Lannett to Submit Biosimilar Application to the US FDA for its Insulin Glargine by the End of 2022
Biosimilars

Lannett to Submit Biosimilar Application to the US FDA for

Tuba Khan June 12, 2020

Shots: Lannett has provided an update on the clinical advancement of its biosimilar Insulin glargine. Following FDA meeting, Lannett has received FDA’s positive feedback on the clinical and CMC advancement of its biosimilar insulin glargine The company anticipates the filing of 351(k) biosimilar application for its biosimilar insulin glargine candidate by the end of 2022 […]Read More

Bayer’s G4A Digital Health Partnerships Program Signs an Agreement with Eleven Digital Health Startups Transforming Digital Health Solutions
DigiHealth

Bayer’s G4A Digital Health Partnerships Program Signs an Agreement with

Vartika Singh October 11, 2019

Shots: The program has two parts Growth Track, in which companies will receive €75 funding for co-creating solutions, as well as co-working space at Bayer’s Pharmaceuticals division headquarters in Berlin, Germany while Advance Track consist of project funds plus incremental milestone-based payments. Mentoring and Coaching is also part of G4ADigital program The partnership will support […]Read More

Astellas Signs a Research and License Agreement with Xencor for Bispecific Antibody Program in Oncology
Biotech

Astellas Signs a Research and License Agreement with Xencor for

Tuba Khan April 3, 2019

Shots: Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for cancer Xencor to utilize its XmAb technology for the development of bispecific Ab candidates against Astellas’ targets & will take care of initial characterization of […]Read More

Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer
Pharma

Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate

Vartika Singh February 14, 2019

Shots: Roche & Vaccibody collaborated to assess the combination of VB10.16 + Tecentriq in P-II, for 50 patients with advanced cervical cancer to evaluate its safety, tolerability, immunogenicity and efficacy The combination trial agreement is built upon the trial assessing VB10.16 monothx in patients with precancerous cervical lesion. Vaccibody plans for the onset of P-II […]Read More

ONO Signs a Research Collaboration with Repare Therapeutics for its Polθ Inhibitor Program
Pharma

ONO Signs a Research Collaboration with Repare Therapeutics for its

Vartika Singh February 1, 2019

Shots: Repare to receive $15M upfront, $160M milestones and royalties on sales of product from ONO. Repare to get exclusive development and commercialization rights for Repare’s Polθ Inhibitor Program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries Repare will retain development and commercialization rights (ex- ONO’s territory) for Polθ Inhibitor Program in […]Read More

Copyright ©2021 PharmaShots | Powered by Octavus Consulting